• Spruce Biosciences reported long-term data for tralesinidase alfa enzyme replacement therapy in Sanfilippo syndrome type B, presented June 4-7, 2026.
• Results included data previously presented at the 22nd Annual WORLD Symposium, extending follow-up to as long as six years.
• Treatment was associated with sustained disease-biomarker improvement, with cognitive function and daily functioning preserved versus declines in untreated natural history patients.
• Imaging and organ assessments were consistent with stabilization of disease-related changes, supporting a potential disease-modifying profile.
• Safety remained broadly consistent with intracerebroventricular delivery over roughly 6,000 administered doses in 22 patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260608285348) on June 08, 2026, and is solely responsible for the information contained therein.